Status:
RECRUITING
Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Collaborating Sponsors:
Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres maladies du motoneurones
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Genetic diagnosis of Amyotrophic Lateral Sclerosis (ALS) could identify the origin of the disease, potentially allowing the patient to pursue targeted/gene therapy. However, many familial forms of ALS...
Eligibility Criteria
Inclusion
- Have a prescription for a genetic diagnosis of ALS (or familial hypercholesterolemia for the control cohort)
- Have given their informed consent for the genetic study and the biobank
- The patient must be a member or beneficiary of a health insurance plan
Exclusion
- The patient is under safeguard of justice or state guardianship
Key Trial Info
Start Date :
November 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT06083584
Start Date
November 22 2023
End Date
May 1 2027
Last Update
May 20 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux
Bordeaux, France
2
CHU de Clermont-Ferrand
Clermont-Ferrand, France
3
CHU de Lyon
Lyon, France
4
La Timone
Marseille, France